Tocilizumab in patients with severe COVID-19 pneumonia in Veracruz, Mexico Page 1 Submit
Manuscript | http://medcraveonline.com objective which was to improve the mortality rate. It also …

Introduction/objectives: An interleukin-6 inhibition strategy could be effective in selected
COVID-19 patients. The objective is to present our experience of tocilizumab use in patients …

Introduction In COVID 19, an aggressive inflammatory response called cytokine release
storm has been described. It is mainly mediated by the activation of Interleukin 6 (IL-6) and …

Abstract Background Coronavirus disease 2019 (Covid-19) pneumonia is often associated
with hyperinflammation. Despite the disproportionate incidence of Covid-19 among …

Recently it has been demonstrated the clinical effectiveness of tocilizumab (TCZ) associated
with systemic steroids for the treatment of severe SARS-CoV-2 pneumonia with rapid …

Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …

Introduction and objectives Tocilizumab is an interleukin-6 receptor-blocking agent
proposed for the treatment of severe COVID-19; however, limited data are available on their …

Purpose This cross-sectional observational study aims to report preliminary data from the
first experience using tocilizumab for patients with severe acute respiratory syndrome …

Background New York City was hard hit by COVID-19. Elmhurst Hospital is a public hospital
in Queens where more than 1500 patients were hospitalized with COVID. During the …

Background The efficacy of interleukin-6 receptor blockade in hospitalized patients with
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …